The Harry Glorikian Show

🎙️ In this episode, we discuss: 00:00 The Journey of an Innovator 06:27 The Birth of a Smartphone ECG 11:29 Overcoming Resistance in Digital Health 16:20 The Evolution of ECG Technology 23:43 The Importance of Early Detection in Cardiac Care 26:20 Innovations in 12-Lead ECG Technology 29:00 AI and Machine Learning in Cardiac Diagnostics 34:23 Remote Monitoring and Patient Empowerment 38:34 Navigat...

🎙️ In this episode, we discuss: 00:00 The Origin Story of Arrive Health 06:04 Rebranding and Evolving Mission 11:50 Real-Time Patient-Specific Drug Costs 18:08 Tackling Prior Authorization Challenges 22:56 Leveraging AI for Healthcare Efficiency 25:36 Understanding Scale and Impact 28:04 Collaboration with Payers and PBMs 30:27 Leveraging AI for Prior Authorization 32:43 Enhancing Access to Medica...

🎙️ In this episode we discuss: 01:06 The founding story of Retina AI 03:56 Why ophthalmology is uniquely suited for AI solutions 06:27 Recent Series B funding and what it means for the company 08:31 How AI integrates into real-world clinical workflows 12:04 AI alerts and notifications for clinical decision support 16:36 Working with pharmaceutical companies on clinical trials 19:15 Predicting dise...

Chapters 00:00 Introduction and Company Updates 02:49 The Digital Transformation of Ultrasound Imaging 06:00 Advancements in Technology and Market Growth 09:03 AI Integration in Medical Imaging 14:50 Impact on Global Health and Humanitarian Efforts 20:55 Challenges in Mainstream Adoption of Handheld Ultrasound 29:43 Strategic Sales Approaches in Medical Devices 34:11 Finding Product-Market Fit 36:...

00:00 Introduction and Overview of Caristo Diagnostics 09:08 The Technology Behind Carry Heart 18:00 Clinical Implications and Risk Assessment 27:27 Actionable Steps for Patients 30:34 Optimizing Cardiovascular Drug Dosing 32:31 AI in Cardiovascular Medicine 33:50 Leveraging Historical Data for Risk Prediction 36:25 AI's Role in Molecular Pathway Analysis 39:03 GLP-1 and Cardiovascular Outcomes 41...

In this episode of The Harry Glorikian Show, host Harry Glorikian welcomes back Jeff Elton, CEO of Concert AI, to discuss the latest advancements in AI-driven healthcare solutions. They reflect on the recent JP Morgan Healthcare Conference, highlighting the optimism surrounding AI's role in transforming drug development and oncology. Jeff shares insights into Concert AI's innovative data ecosystem...

Harry's guest this week is Raffi Krikorian, chief technology officer and managing director at Emerson Collective, the social change organization founded by Laurene Powell Jobs. Krikorian is the former vice president of engineering at Twitter (now X), where he was responsible for getting rid of the Fail Whale and making the company’s backend infrastructure more reliable; the former director of Uber...

Generative AI is going to change how we do things across the entire economy, including the fields Harry covers on the show, namely healthcare delivery, drug discovery, and drug development. But we’re still just starting to figure out exactly how it’s going to change things. For example, AI is already speeding up the process of discovering new biological targets for drugs and designing molecules to...

If you learned that radiologists looking at CT scans for the traditional signs of coronary artery disease catch only 20 percent of the people who actually have a high risk of a heart attack, and if you learned that there’s a new AI-based test that can catch subtle signs of inflammation in the other 80 percent of patients—well, you’d probably want to get that test yourself, right? Harry's guests th...

Investors and companies in the life science industry have been betting a lot of money over the last few years on a single idea: that computation will help us get a lot better at developing new drugs. But the word “computation” covers a pretty broad range of techniques. And the reason that there are dozens if not hundreds of computational drug discovery startups popping up is that everyone has thei...

If you look back at all the health-tech and drug development companies Harry has hosted on the show, an interesting pattern starts to emerge: a very large number of those companies have gone on to enormous growth and success in their markets. It could be that being on the podcast is like a catapult to success—or it could be that we're pretty good at finding companies that are already on a promisin...

One of the most amazing successes in the battle against cancer over the last two decades has been the introduction of antibody drugs that harness the body’s own immune system to kill tumor cells. Finding those drugs may sound like a biology problem rather than a machine learning or a big-data problem. But actually, these days, it’s both. Harry's guest this week is Leonard Wossnig, who’s the chief...

The combination of better data and more powerful computing is helping researchers reinvent the process of discovering new drugs. Within 5-10 years, we’ll likely see a huge wave of new medicines that were either discovered or designed using AI—drugs that will finally help us get control of our most stubborn health problems, from cancer to cardiovascular disease to obesity and metabolic disorders to...

There are about 30 trillion human cells in your body, but there are about 38 trillion  bacterial cells, mostly hanging out in your large intestine. And that’s not even counting all the viruses, fungi, protists, and other microbial cells that live on your skin, in your bloodstream, and all around your body. So in effect, what you think of as you is not really you. You’re actually a walking colony o...

Quality control is one of those things that only a select few people pay attention to—until something goes wrong, then everyone cares. That's especially true in the drug manufacturing industry, where episodes like cross-contamination in a drug factory can shut down a production line and create instant shortages of important medicines. And if a contaminated medicines ever does get shipped out to cl...

There’s a lot of talk out there about how artificial intelligence will change the way doctors and nurses take care of patients; you hear some of it right here on this show. But all of that still feels like a forecast rather than a present reality. When you look really closely, it’s hard to find concrete examples where AI is already helping healthcare providers make better decisions that improve pa...

There’s a good chance that we’re all going to live a lot longer than we think. Or at least, that’s what Harry's guest Sergey Young argues in his book The Science and Technology of Growing Young . Young is an investor who leads a $100 million venture capital fund called the Longevity Vision Fund, and through his investing, he says he meets innovators who are coming up with the technologies that wil...

It's practically the theme of our show that AI is going to change almost everything about the way drugs get developed and the way healthcare gets delivered. But there’s probably nobody better placed to see how this transformation is already happening than Harry's guest this week, Scott Penberthy.  Scott works at Google Cloud, where he’s the director of Applied AI in the Office of the CTO. He and h...

Building any kind of startup is hard. Starting a business in healthcare or medical technology is even more challenging, given the long timelines for product development and all the regulatory requirements companies have to meet. But imagine how much harder it would be to start a company if you were still just a senior in high school!  Recently Harry learned about a company called Vytal that’s buil...

If you’re looking for help thinking about the implications of exponential change in all areas of technology, one of the best people you can turn to is Azeem Azhar. He's a writer, entrepreneur, and investor who publishes the incredibly popular and influential Substack newsletter Exponential View, which takes deep dives into AI and other subjects with world experts. In 2021 Azeem published a whole b...

It’s been less than a year since OpenAI opened up ChatGPT to the general public, and less than six months since OpenAI introduced GPT-4, the large language model that currently powers ChatGPT. But in that brief time, the new crop of generative AI tools from OpenAI and competitors like Google and Anthropic has already started to transform the way we think about managing information. We’re entering...

Harry's guest this week is Joe DeVivo, the new CEO of Butterfly Network. The company's goal is to make it radically easier for doctors or medical technicians to perform an ultrasound exam on any part of the body, and radically cheaper for a patient to get one. The companyt makes an FDA-cleared, handheld ultrasound scanner called the Butterfly iQ. The first big thing that’s different about the iQ i...

This week Harry's guest is....Harry! We're flipping the script and giving Harry a chance to wax eloquent about AI in healthcare and drug research, the growing role of personal health monitoring devices, the unique features of the Boston life science ecosystem, the meaning of the recent downturn in biotech investment, the most common mistakes made by new entrepreneurs, and much more. This week's gu...

Harry's guest this week is Dr. Isaac Kohane, chair of the Department of Biomedical Informatics at Harvard Medical School and co-author of the new book The AI Revolution in Medicine: GPT-4 and Beyond . Large language models such as GPT-4 are obviously starting to change industries like search, advertising, and customer service—but Dr. Kohane says they're also quickly becoming indispensable referenc...

In the same way that written English is built around an alphabet of just 26 letters, all life on Earth is built around a standard set of just 20 amino acids, which are the building blocks of all proteins. And just as we've invented special characters like emoji to go beyond our standard letters, it turns out that biologists can expand their repertoire of powers using non-standard amino acids—those...